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UTILIZING PERIPHERAL BLOOD CD34 COUNT AS A PREDICTOR FOR THE
NEED FOR PLERIXAFOR IN AUTOLOGOUS STEM CELL MOBILIZATION –
SINGLE INSTITUTION EXPERIENCE
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Background: Mobilization and collection of sufficient autologous he-
matopoietic stem cells (AHSC) is crucial for success of autologous stem
cell transplantation. Moncada et al. reported 14% of patients receiving
chemotherapy and GCSF for AHSC donation fail to mobilize enough
AHSC for transplant (Transfusion 43:495ff, 2003). Plerixafor 1 GCSF
resulted in 3-fold higher rate of patients achieving the targeted CD34
count in fewer AHSC collections (DiPersio et al. Blood 110:601ff,
2007). Plerixafor use in all patients is unnecessary and unlikely cost-ef-
fective. At UIHC (chemo-mobilized patients were excluded from this
analysis), all patients undergoing AHSC collection receive GCSF daily
for 5 d prior to leukapheresis. Peripheral bloodCD34 (PBCD34) count
on themorningofday4 isobtained. If thePBCD34#8/mL,plerixafor is
administered that evening followed byGCSF the nextmorning (P1G),
however if the PBCD34 count is. 8, AHSC collection proceeds with-
out plerixafor (G). The goal of this study is to evaluate our current prac-
tice in utilizing PBCD34 as a predictor of the need for plerixafor.
Methods/Results:We retrospectively reviewed data on patients mo-
bilized at UIHC for AHSC collections following the implementation
of the previous algorithm between Jan 2009 & Aug 2010. 78 patients
were analyzed: 32 in the P1G group and 46 in the G group. Patients’
characteristics are displayed inTable 1. Almost all patients in the P1G
group (30/32) had undetectable PBCD34 on d 4 (2 patients had
PBCD34 of 3 and 8/mL), compared to a median of 24/[sup]m[/sup]L
(mean 31.5, SD 17.95) in the G group (p \ 0.0001). All patients
reached their targets in # 3 collections. No mobilization failures oc-
curred. There was no significant difference in the number of collec-
tions (p 5 0.32) or in the final product CD34 counts between the
two groups (p 5 0.15) (P1G mean 8.2*106 1/-5.0, G mean 6.6*106
1/-5.5). More than 2/3 of the patients in P1G group (n 5 22,
68.8%) reached their CD34 target on first day of collection compared
to 56.5% (n 5 26) from G group (p 5 0.14). (P1G mean 7.3*106
1/-5.6, Gmean 5.4*1061/-5.6). In the P1Ggroup 5 patients needed
2 collections and 5 patients needed 3 collections to reach their target
compared to 14 and 6 in the G group respectively.
Conclusion: Despite unmeasurably low PBCD34 count in the pe-
ripheral blood the day prior to AHSC collection, plerixafor permit-
ted these patients to collect at least as well as patients with. 8 cells/
mL, usually in a single session.
Table 1. Patients’ Characteristics
P+G group G group
(n532) (n546) p-valueAge (Median, Mean, SD) 60, 55.8, 13.7 56, 51.6, 13.2 0.18
Gender (Male:Female) 14:18 26:20 0.27
Diagnosis:
Multiple Myeloma (42%) 15 18 0.64
Hodgkin Lymphooma (18%) 4 10 0.37
Non Hodgkin Lymphoma (40%) 13 18 1
Prior Therapy: 0.88
Chemotherapy only 26 38
Chemotherapy and Radiation 6 8
Number of prior chemotherapy
cycles (Median, Mean, SD)
8.5, 8.6, 4.1 9, 7.8, 3.2 0.68Target CD34 count in the final
product of collection
(Median, Mean, SD)3, 4, 1.55 3, 4, 1.45 0.72127
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Introduction: High dose chemotherapy and autologous stem cell
transplant (HD-SCT) improve disease free (DFS) and overallsurvival (OS) and can be curative in various hematologic malignan-
cies. HD-SCT is also associated with significant morbidity and
hence is not routinely offered to elderly patients.
Methods: In this study we describe our experience in patients aged
70 years or above who underwent HD-SCT between 2000 and 2010.
Data was collected from retrospective review of our transplant regis-
try and medical records and was analyzed utilizing SPSS v13.
Results: Twenty patients aged 70 years or above underwent HD-
SCT for a variety of hematologic malignancies (10 patients with
Multiple Myeloma, 9 with Non-Hodgkin Lymphoma and 1 with
Hodgkin Lymphoma). Median age of the patients was 71 years
(range 70-76). All patients had a good performance status (median
ECOGPS was 1, range 0-1) at the time of transplant. 80% of the pa-
tients were males and 60% were in a complete remission at the time
of transplant. Conditioning was with BEAM for NHL and HL pa-
tients (20% required dose adjustment due to co-morbid conditions)
andMelphalan forMMpatients (20% received 140mg/m2 due to re-
nal function). The mean CD34 cells collected was 7.5x106 cells/kg
and the number infused was 5.54 x106 cells/kg. All patients engrafted
and the median number of days for neutrophil engraftment was 10
and for platelets was 12. Overall the transplant process was well tol-
erated with mucositis being the most common complication seen in
40% of the patients (grades 1-3). Other complications included diar-
rhea (10% grade 1-2 and 20% grade 3-4), febrile neutropenia (20%
grade 3-4), sepsis (15% grade 3-4) and atrial fibrillation (10% grade
1-2). The estimated 5-year overall survival is 56.7% and 5-year
progression free survival is 55.4%. There were no deaths during
the immediate transplant process.
Conclusions: Our data suggests that in a well-selected elderly pop-
ulation older than 70 years HD-SCT appears to be a well tolerated
therapeutic option. We therefore recommend that age should not
be utilized as sole exclusion criteria for patients undergoing HD-
SCT for their various hematologic malignancies.128
BORTEZOMIB FOLLOWED BY A PHASE I STUDY OF BORTEZOMIB IN
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Preclinical and non-transplant clinical data indicates synergism be-
tween melphalan and bortezomib with enhanced melphalan-induced
DNA damage via bortezomib-mediated down regulation of Fanconi
anemia (FA)/BRCA DNA repair pathway. We designed a trial to ex-
amine the sequencing of high dose melphalan (100 mg/m2/day  2
days), immediately followed by one dose of bortezomib (0.7, 1.0, or
1.3 mg/m2 on a phase I study design) and tandem autologous trans-
plants. Thirty patients with primary refractory multiple myeloma or
plasma cell leukemia were treated between 05/2005 and 02/2009.
The patients received 2 cycles of preconditioning bortezomib (1. 3
mg/m2) and proceeded with transplants. The median age was 54.5
years (range, 36 – 70 years). The median beta 2-microglobulin was
4.35 mg/L (range: 1.8-11.4); albumin was 3.7 g/dL (range: 3.1-4.9).
Preconditioning bortezomib resulted in 1 complete response (CR), 1
very good partial response (VGPR), 9 partial response (PR), 13 stable
disease (SD), 3 progressive disease (PD) and 3 patients were not evalu-
able. The overall response rate (ORR) was 36%. A total of 25 patients
proceeded with transplants. By 90 days, we documented 5 CR, 6
VGPR, 10 PR and 1 SDpost tandem transplants. TheORR increased
to 84% at the peak of best response with 9 CR, 3 VGPR, and 9 PR.
With a median follow-up of 24.5 months (range, 3 – 62 months), the
median progression-free survival from the first dose of bortezomib
was 15 months (95% CI: 11 – 20 months) and the median overall
